GO:1901081 negative regulation of relaxation of smooth muscle: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901081 describes any process that stops, prevents, or reduces the frequency, rate, or extent of smooth muscle relaxation.
• It is a biological_process term that opposes the signaling and ion flux changes required for smooth muscle cells to return to a low-tone state.
• Key molecular players include BK channels (KCNMA1, KCNMB1), L-type Ca2+ channels, RhoA/Rho-kinase, and caldesmon.
• Dysregulation of this process contributes to hypertension, bladder dysfunction, and vascular remodeling.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of candidate genes in this pathway.
• Targeting negative regulation of smooth muscle relaxation is a therapeutic strategy for urological and cardiovascular disorders.
Description
Smooth muscle relaxation is an active, energy-dependent process that lowers intracellular Ca2+ and reduces myosin light chain phosphorylation, allowing muscle cells to return to a low-tone state. The Gene Ontology term GO:1901081, negative regulation of relaxation of smooth muscle, captures any process that stops, prevents, or reduces the frequency, rate, or extent of this relaxation. This term is essential for understanding how tissues such as blood vessels, airways, and the lower urinary tract maintain or modulate tone under physiological and pathological conditions. Researchers study GO:1901081 because its dysregulation underlies major human diseases, including hypertension, overactive bladder, and vascular remodeling. The process integrates ion channel activity, Ca2+ signaling, and cytoskeletal regulation, making it a rich area for mechanistic and translational investigation.
negative regulation of relaxation of smooth muscle At A Glance
| GO ID | GO:1901081 |
|---|---|
| GO term | negative regulation of relaxation of smooth muscle |
| Ontology | biological_process |
| Synonym | down regulation of relaxation of smooth muscle; down-regulation of smooth muscle relaxation; inhibition of smooth muscle relaxation |
| Major function | Opposes the signaling and ion flux changes that lead to smooth muscle relaxation |
| Related processes | Regulation of smooth muscle contraction, calcium ion homeostasis, Rho signaling |
| Key regulators | BK channels (KCNMA1, KCNMB1), L-type Ca2+ channels, RhoA/Rho-kinase, caldesmon |
| Disease relevance | Hypertension, overactive bladder, vascular remodeling |
What Is GO:1901081?
GO:1901081 is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of relaxation of smooth muscle. In practice, this means molecular events that oppose the return of a contracted smooth muscle cell to a relaxed state, such as sustained Ca2+ influx, inhibition of Ca2+ clearance, or activation of RhoA/Rho-kinase signaling that maintains myosin light chain phosphorylation.
Why Is negative regulation of relaxation of smooth muscle Important in Cell Biology?
GO:1901081 is important because it defines the molecular brakes on smooth muscle relaxation, a process critical for controlling blood pressure, urine storage, and airway diameter. When these brakes fail or become overactive, tissues cannot relax properly, leading to conditions such as hypertension, bladder dysfunction, and vascular remodeling. Understanding this term helps researchers identify therapeutic targets and design experiments to modulate smooth muscle tone.
• Controls vascular tone and blood pressure by opposing relaxation of arterial smooth muscle.
• Regulates bladder filling and voiding; dysfunction leads to overactive bladder or retention.
• Involves BK channel subunits such as KCNMB1, whose reduced expression causes vascular smooth muscle phenotypic switch and apoptosis.
• RhoA/Rho-kinase signaling negatively regulates relaxation by maintaining myosin light chain phosphorylation.
• Caldesmon modulates preglomerular renal vascular tone, affecting kidney function.
• Calcium sparks and BK channels are key regulators of smooth muscle relaxation and its negative control.
• Ecto-5'-nucleotidase influences bladder function, linking purinergic signaling to relaxation control.
• Dysregulation contributes to hypertension, overactive bladder, and vascular remodeling.
• Provides targets for pharmacological intervention in urological and cardiovascular diseases.
• Enables mechanistic studies using CRISPR models to test causal roles of specific genes.
What Happens During negative regulation of relaxation of smooth muscle?
Sustained intracellular Ca2+ and inhibition of Ca2+ clearance
In simple terms: Keeping calcium levels high inside the cell prevents the muscle from relaxing.
Relaxation of smooth muscle requires a drop in intracellular Ca2+ concentration, which is achieved by closing L-type Ca2+ channels and removing Ca2+ via pumps and exchangers. Negative regulation of relaxation can occur when Ca2+ influx persists or when Ca2+ clearance mechanisms are inhibited, maintaining high cytosolic Ca2+ and preventing relaxation. Calcium sparks, local Ca2+ release events from ryanodine receptors, can activate BK channels to oppose Ca2+ influx, but their disruption can also contribute to negative regulation.
BK channel modulation and membrane potential
In simple terms: BK channels act as a brake on contraction, but when they are lost, relaxation is impaired.
Large-conductance Ca2+-activated K+ (BK) channels, composed of KCNMA1 and regulatory subunits such as KCNMB1, hyperpolarize the membrane and promote relaxation. Reduced expression of KCNMB1 leads to vascular smooth muscle cell phenotypic switch and apoptosis, which can negatively regulate relaxation by altering the cell's ability to respond to relaxing stimuli. In the lower urinary tract, BK-RyR coupling is critical for normal relaxation, and its disruption contributes to pathophysiology.
RhoA/Rho-kinase signaling and cytoskeletal regulation
In simple terms: RhoA signaling keeps the muscle contracted by preventing the cytoskeleton from disassembling.
RhoA/Rho-kinase signaling negatively regulates smooth muscle relaxation by inhibiting myosin light chain phosphatase, thereby maintaining myosin light chain phosphorylation and contraction. Insulin and nitric oxide/cGMP pathways can counteract Rho signaling, promoting relaxation. Caldesmon, an actin-binding protein, modulates preglomerular renal vascular tone and can negatively regulate relaxation by stabilizing actin-myosin interactions.
Purinergic and ecto-5'-nucleotidase pathways
In simple terms: Adenosine signaling can influence how well the bladder muscle relaxes.
Ecto-5'-nucleotidase (CD73) generates adenosine, which modulates bladder function. Alterations in this pathway can negatively regulate relaxation by affecting purinergic signaling and smooth muscle tone. This highlights the role of extracellular nucleotide metabolism in controlling smooth muscle relaxation.
Integration of negative regulatory inputs
In simple terms: Multiple signals work together to decide whether the muscle stays contracted or relaxes.
Negative regulation of relaxation integrates ion channel activity, Ca2+ handling, RhoA/Rho-kinase signaling, and cytoskeletal dynamics. For example, sustained Ca2+ influx and RhoA activation can override relaxant signals, while BK channel opening and caldesmon modulation can tip the balance toward relaxation. Understanding these integrated inputs is key to identifying therapeutic targets.
Key Genes Involved in GO:1901081 negative regulation of relaxation of smooth muscle
The following genes and proteins are central to the negative regulation of smooth muscle relaxation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KCNMA1 | Alpha subunit of BK channels; promotes relaxation | Target for modulating vascular and bladder tone |
| KCNMB1 | Regulatory subunit of BK channels; reduced expression causes phenotypic switch | Linked to vascular smooth muscle apoptosis and relaxation defects |
| RYR1 | Ryanodine receptor; mediates Ca2+ sparks | Couples to BK channels in lower urinary tract |
| RYR2 | Ryanodine receptor; mediates Ca2+ sparks | Couples to BK channels in lower urinary tract |
| CACNA1C | L-type Ca2+ channel; mediates Ca2+ influx | Sustained influx opposes relaxation |
| RHOA | Small GTPase; activates Rho-kinase | Negatively regulates relaxation via MLC phosphatase inhibition |
| ROCK1 | Rho-kinase; inhibits MLC phosphatase | Key effector of RhoA in smooth muscle |
| ROCK2 | Rho-kinase; inhibits MLC phosphatase | Key effector of RhoA in smooth muscle |
| CALD1 | Caldesmon; actin-binding protein | Modulates renal vascular tone |
| MYLK | Myosin light chain kinase; phosphorylates MLC | Promotes contraction, opposes relaxation |
| PPP1R14A | CPI-17; inhibits MLC phosphatase | Enhances contraction, negatively regulates relaxation |
| NT5E | Ecto-5'-nucleotidase (CD73); generates adenosine | Modulates bladder function |
| ADORA1 | Adenosine receptor A1 | Mediates purinergic effects on bladder relaxation |
| ADORA2A | Adenosine receptor A2A | Mediates purinergic effects on bladder relaxation |
| PRKG1 | cGMP-dependent protein kinase; promotes relaxation | Counteracts RhoA signaling |
| NOS3 | Endothelial nitric oxide synthase; produces NO | Promotes relaxation via cGMP |
| GUCY1A1 | Soluble guanylate cyclase subunit; produces cGMP | Mediates NO-induced relaxation |
| IR | Insulin receptor; activates NO/cGMP pathway | Negative regulation of Rho signaling |
How Is negative regulation of relaxation of smooth muscle Regulated?
The negative regulation of smooth muscle relaxation is itself regulated by upstream signaling pathways. Insulin and nitric oxide/cGMP signaling can inhibit RhoA/Rho-kinase, thereby promoting relaxation and counteracting negative regulation. Conversely, sustained Ca2+ influx through L-type channels and reduced BK channel activity enhance negative regulation. Caldesmon and ecto-5'-nucleotidase further modulate the process in a tissue-specific manner.
negative regulation of relaxation of smooth muscle and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KCNMB1 | Vascular smooth muscle phenotypic switch and apoptosis | Knockout and overexpression in vascular smooth muscle cells |
| CALD1 | Renal vascular tone dysregulation | Knockout in preglomerular renal vasculature |
| NT5E | Bladder dysfunction | Knockout in bladder smooth muscle |
| RHOA | Hypertension and vascular remodeling | Point mutation and knockout in vascular smooth muscle |
| RYR2 | Lower urinary tract dysfunction | Knock-in of disease-associated mutations |
Vascular dysfunction and hypertension
Reduced expression of KCNMB1 leads to vascular smooth muscle cell phenotypic switch and apoptosis, impairing relaxation and contributing to vascular dysfunction. Caldesmon regulation of preglomerular renal vasculature affects kidney function and blood pressure. These mechanisms link negative regulation of relaxation to hypertension and vascular remodeling.
Lower urinary tract dysfunction
BK-RyR coupling in the lower urinary tract is critical for normal bladder relaxation; its disruption contributes to overactive bladder and other voiding dysfunctions. Ecto-5'-nucleotidase (CD73) modulates bladder function through adenosine signaling, and its dysregulation can affect relaxation.
Smooth muscle phenotypic switch and apoptosis
Loss of KCNMB1 causes vascular smooth muscle cells to switch phenotype and undergo apoptosis, which negatively impacts relaxation and tissue homeostasis. This highlights the importance of BK channel subunits in maintaining a relaxed, contractile-competent state.
From negative regulation of relaxation of smooth muscle-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of KCNMB1 impair smooth muscle relaxation? | KCNMB1 knockout in vascular smooth muscle cells |
| Does a specific point mutation in RHOA alter relaxation? | RHOA point mutation knock-in in smooth muscle |
| Does overexpression of CALD1 affect renal vascular tone? | CALD1 overexpression in preglomerular renal vasculature |
| Does tagging BK channels reveal their localization? | Tagged knock-in of KCNMA1 |
| Does knockout of NT5E alter bladder function? | NT5E knockout in bladder smooth muscle |
| Does a disease-associated RYR2 mutation affect BK-RyR coupling? | RYR2 knock-in in lower urinary tract smooth muscle |
How to Study the negative regulation of relaxation of smooth muscle Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Calcium imaging | Intracellular Ca2+ concentration | Assess relaxation and Ca2+ clearance |
| Patch-clamp electrophysiology | Membrane potential and ion channel activity | Study BK and L-type channel function |
| Isometric tension recording | Smooth muscle contractility and relaxation | Test pharmacological modulators |
| Western blotting | Protein expression levels | Quantify KCNMB1, RhoA, caldesmon |
| Rho-kinase activity assay | Rho-kinase enzymatic activity | Measure negative regulation via RhoA |
| CRISPR knockout screening | Gene essentiality for relaxation | Identify novel negative regulators |
| Co-immunoprecipitation | Protein-protein interactions | Study BK-RyR coupling |
Calcium imaging and electrophysiology
Measuring intracellular Ca2+ and membrane potential using fluorescent indicators and patch-clamp allows direct assessment of relaxation and its negative regulation. Calcium sparks can be visualized with confocal microscopy to study BK-RyR coupling.
Tension and contractility assays
Isometric tension recordings on isolated smooth muscle strips quantify relaxation responses to pharmacological agents, revealing negative regulatory inputs. These assays are standard for studying vascular and bladder smooth muscle.
Molecular and biochemical assays
Western blotting, co-immunoprecipitation, and Rho-kinase activity assays measure protein expression and signaling changes underlying negative regulation. These methods help link gene expression to functional outcomes.
CRISPR-based genetic screens
Pooled CRISPR knockout screens can identify genes that negatively regulate smooth muscle relaxation, followed by validation in individual knockouts. This approach is powerful for discovering novel regulators.
How CRISPR Can Be Used to Study GO:1901081 negative regulation of relaxation of smooth muscle
Knockout
CRISPR knockout of genes such as KCNMB1 or NT5E in smooth muscle cells can reveal their causal role in negative regulation of relaxation. Knockout models show phenotypic changes like impaired relaxation or apoptosis, validating gene function.
Point Mutation
Introducing point mutations in genes like RHOA or RYR2 allows testing of specific amino acid residues in negative regulation. This is useful for dissecting signaling domains and disease-associated variants.
Knock-in
Knock-in of tagged versions of BK channels or disease-associated mutations enables tracking of protein localization and function in vivo. This approach provides physiological relevance.
Overexpression
Overexpression of CALD1 or KCNMB1 can test gain-of-function effects on smooth muscle relaxation. This helps determine whether increased levels of a protein enhance or suppress negative regulation.
How EDITGENE Supports negative regulation of relaxation of smooth muscle Research
Researchers studying negative regulation of relaxation of smooth muscle-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated with it. EDITGENE provides the tools to make that determination through precise genome editing.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of relaxation of smooth muscle research.
Frequently Asked Questions About negative regulation of relaxation of smooth muscle
What is GO:1901081?
GO:1901081 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of relaxation of smooth muscle.
What genes are involved in negative regulation of relaxation of smooth muscle?
Key genes include KCNMA1, KCNMB1, RHOA, ROCK1, ROCK2, CALD1, and NT5E, among others.
How does negative regulation of smooth muscle relaxation work?
It involves sustained intracellular Ca2+, BK channel modulation, RhoA/Rho-kinase signaling, and cytoskeletal regulation that oppose relaxation.
What diseases are associated with negative regulation of relaxation of smooth muscle?
Hypertension, overactive bladder, vascular remodeling, and renal vascular dysfunction are linked to dysregulation of this process.
What is the role of KCNMB1 in smooth muscle relaxation?
KCNMB1 encodes a regulatory subunit of BK channels; reduced expression leads to vascular smooth muscle phenotypic switch and apoptosis, impairing relaxation.
How does RhoA signaling negatively regulate smooth muscle relaxation?
RhoA activates Rho-kinase, which inhibits myosin light chain phosphatase, maintaining myosin light chain phosphorylation and preventing relaxation.
What research methods are used to study negative regulation of smooth muscle relaxation?
Calcium imaging, patch-clamp, tension recordings, Western blotting, and CRISPR screens are commonly used.
Can CRISPR be used to study negative regulation of smooth muscle relaxation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of candidate genes.
What is the role of caldesmon in renal vascular tone?
Caldesmon modulates preglomerular renal vascular tone, affecting kidney function and blood pressure.
How does ecto-5'-nucleotidase affect bladder function?
Ecto-5'-nucleotidase (CD73) generates adenosine, which modulates bladder smooth muscle function and relaxation.
Conclusion
GO:1901081, negative regulation of relaxation of smooth muscle, is a critical biological process that controls smooth muscle tone by opposing relaxation. Its dysregulation contributes to major diseases such as hypertension and bladder dysfunction. Understanding the genes and mechanisms involved, from BK channels to RhoA signaling, provides opportunities for therapeutic intervention. CRISPR-based models are powerful tools for dissecting these pathways and identifying new targets.
References
- 2. Liu H et al.. 2025. Reduced expression of KCNMB1 leads to vascular smooth muscle cell phenotypic switch and apoptosis.. Biochem Pharmacol 241:117151 PMID: 40653026
- 3. Ridlon M et al.. 2025. Smooth muscle of the lower urinary tract: BK-RyR coupling in physiology and pathophysiology.. J Muscle Res Cell Motil 46(4):487-505 PMID: 40889018
- 4. Thorneloe KS et al.. 2005. Ion channels in smooth muscle: regulators of intracellular calcium and contractility.. Can J Physiol Pharmacol 83(3):215-42 PMID: 15870837
- 5. Jaggar JH et al.. 2000. Calcium sparks in smooth muscle.. Am J Physiol Cell Physiol 278(2):C235-56 PMID: 10666018
- 6. Barge S et al.. 2024. Role of ecto-5'-nucleotidase in bladder function.. FASEB J 38(2):e23416 PMID: 38198186
- 7. Begum N et al.. 2002. Negative regulation of rho signaling by insulin and its impact on actin cytoskeleton organization in vascular smooth muscle cells: role of nitric oxide and cyclic guanosine monophosphate signaling pathways.. Diabetes 51(7):2256-63 PMID: 12086958
- 8. Pryymachuk G et al.. 2026. Regulation of Vascular Tone of Preglomerular Renal Vasculature by Caldesmon.. J Am Heart Assoc 15(2):e046679 PMID: 41553092
